Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Immune Targeting Systems Ltd
ClinicalTrials.gov Identifier:
NCT01701752
First received: October 3, 2012
Last updated: July 26, 2013
Last verified: July 2013
  Purpose

This study will evaluate the safety and immunogenicity of FP-01.1 and FP-01.1 reformulated with an adjuvant (FP-01.1-Adjuvant) in relatively healthy subjects 65 to 74 years of age, subjects that are more representative of the target population. Both formulations will be administered alone or concomitantly with the Trivalent Inactivated Influenza Virus (TIV) vaccine.


Condition Intervention Phase
Influenza A
Biological: FP-01.1 + Placebo
Biological: FP-01.1 + TIV
Biological: FP-01.1-Adjuvant + Placebo
Biological: FP-01.1-Adjuvant + TIV
Biological: Adjuvant + TIV
Biological: Placebo + TIV
Biological: FP-01.1
Biological: FP-01.1-Adjuvant
Other: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomised, Double Blind, Double Observer Study to Assess Repeated Administration of a Single Dose of an Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Dose of a Trivalent Inactivated Influenza Virus Vaccine in Subjects 65 to 74 Years of Age.

Resource links provided by NLM:


Further study details as provided by Immune Targeting Systems Ltd:

Primary Outcome Measures:
  • Number and proportion of subjects reporting solicited local reactions and severity of the local reactions [ Time Frame: Day 1- 209 ] [ Designated as safety issue: Yes ]
  • To assess and compare the immunogenicity response between groups [ Time Frame: Day 1- 209 ] [ Designated as safety issue: No ]
    The immunogenicity of two different formulations of FP-01.1 after each vaccine injection in each treated group

  • Number and proportion of subjects reporting unsolicited AEs and Serious Adverse Events (SAEs) [ Time Frame: Day 1- 209 ] [ Designated as safety issue: Yes ]
  • Number and proportion of subjects with abnormal haematology, blood chemistry lab assessments [ Time Frame: Day 1- 209 ] [ Designated as safety issue: Yes ]
  • Number and proportion of subjects with abnormal vital signs/ECG assessments [ Time Frame: Day 1 - 209 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Exploratory immunogenicity tests on samples obtained from subjects [ Time Frame: Day 1 -209 ] [ Designated as safety issue: No ]
  • To assess the impact of FP-01.1 and FP-01.1-Adjuvant on the immune response to TIV [ Time Frame: Day 1-209 ] [ Designated as safety issue: No ]

Enrollment: 120
Study Start Date: September 2012
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Group 1
Day 1: FP-01.1 + Placebo ; Day 29: FP-01.1
Biological: FP-01.1 + Placebo Biological: FP-01.1
Active Comparator: Group 2
Day 1: FP-01.1 + TIV ; Day 29: FP-01.1
Biological: FP-01.1 + TIV Biological: FP-01.1
Active Comparator: Group 3
Day 1: FP-01.1-Adjuvant + Placebo ; Day 29: FP-01.1-Adjuvant
Biological: FP-01.1-Adjuvant + Placebo Biological: FP-01.1-Adjuvant
Active Comparator: Group 4
Day 1: FP-01.1-Adjuvant + TIV ; Day 29: FP-01.1-Adjuvant
Biological: FP-01.1-Adjuvant + TIV Biological: FP-01.1-Adjuvant
Active Comparator: Group 5
Day 1: Adjuvant + TIV ; Day 29: Placebo
Biological: Adjuvant + TIV Other: Placebo
Active Comparator: Group 6
Day 1: Placebo + TIV ; Day 29: Placebo
Biological: Placebo + TIV Other: Placebo

  Eligibility

Ages Eligible for Study:   65 Years to 74 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 65 to 74 years inclusive at the time of consent
  • Female subjects will be post-menopausal (no menses for at least 2 years) and therefore of non-child bearing potential
  • Male subjects willing to comply with the applicable contraceptive requirements of the protocol, e.g. must agree to refrain from fathering a child until after the safety follow up visit. Male subjects do not need to use contraception if their partner has been through the menopause, or has had a hysterectomy or bilateral oophorectomy. If a male subject's partner is of child bearing potential, male subjects must agree to use a barrier method (condom) as a method of birth control in addition to any contraceptive measures normally taken by his partner, until after the safety follow up visit.
  • Satisfactory medical assessment with no clinically significant or relevant abnormalities in medical history, physical examination, vital signs, ECG and laboratory evaluation (haematology & biochemistry) as assessed by the Investigator in relation to the age of the patient.
  • An understanding, ability and willingness to fully comply with study procedures and restrictions
  • Ability to provide written, personally signed and dated informed consent to participate in the study.
  • The subject has a BMI < 35.

Exclusion Criteria:

  • As a result of the medical screening process, the Principal Investigator or Co- Investigator considers the subject unfit for the study.
  • Women of child-bearing potential
  • Clinically significant , uncontrolled, current, chronic or recurrent disease, as deemed by the Investigator, (e.g. cardiovascular, respiratory, endocrine, renal, liver, gastrointestinal, autoimmune, immune suppression, malignancy or other conditions) that could affect the action, absorption or disposition of the IMP or could affect clinical or laboratory assessments.
  • Significant illness as judged by the Principal Investigator or Co-Investigator within 2 weeks of the first dose of IMP.
  • Subjects with a history of allergies or allergic conditions including anaphylactic reactions, asthmatics, hay fever, allergy to egg products and eczema sufferers requiring medication which in the opinion of the Principal Investigator or Co- Investigator will affect their participation in the study.
  • Subjects receiving medications that affect the immune system including systemic steroids at a dose greater than 5mg and patients on chronic medications where the dose has not been stable for at least 3 months. Inhaled or topical steroids will be allowed.
  • Known or suspected intolerance or hypersensitivity to the IMP, or closely related compounds or any of the stated ingredients.
  • Male subjects who consume more than 21 units of alcohol per week and female subjects who consume more than 14 units of alcohol per week.
  • A positive HIV antibody screen, Hepatitis B surface antigen, Hepatitis B core antibody, or Hepatitis C antibody screen
  • Subjects who have significant scarring, tattoos, abrasions, cuts or infections, that in the opinion of the Investigator could interfere with evaluation of injection site local reactions, over the deltoid region of both arms as these will be the dose site.
  • Donation of blood or blood products (e.g. plasma, platelets) within 90 days prior to or intention to donate blood during the entire study.
  • Use of another investigational medicinal product within 90 days prior to receiving the first dose of IMP or intention to enrol in another clinical study throughout the entire study including the follow up period.
  • Subject with suspected recent (≤6 months) experience of influenza-like illness (fever [>37.8ºC] and cough and/or sore throat > 2 days- in the absence of a known cause other than influenza)
  • Subjects who have received a flu vaccine in the last 6 months
  • Any clinically significant abnormalities, in the opinion of the Principal Investigator or Co-Investigator, on electrocardiograms (ECGs)
  • In addition, for each subject, a completed medical history questionnaire will be taken as part of the consented study procedure.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01701752

Sponsors and Collaborators
Immune Targeting Systems Ltd
Investigators
Principal Investigator: Geert Leroux-Roels, Professor Centre for Vaccinology, Ghent University Hospital
  More Information

No publications provided

Responsible Party: Immune Targeting Systems Ltd
ClinicalTrials.gov Identifier: NCT01701752     History of Changes
Other Study ID Numbers: FP-01.1_CS_03
Study First Received: October 3, 2012
Last Updated: July 26, 2013
Health Authority: Belgium: Federal Agency for Medicines and Health Products, FAMHP

Keywords provided by Immune Targeting Systems Ltd:
Influenza A

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on April 22, 2014